Publications by authors named "B Schenk"

Background & Aims: Follow-up (FU) strategies after endoscopic eradication therapy (EET) for Barrett's neoplasia do not consider the risk of mortality from causes other than esophageal adenocarcinoma (EAC). We aimed to evaluate this risk during long-term FU, and to assess whether the Charlson Comorbidity Index (CCI) can predict mortality.

Methods: We included all patients with successful EET from the nationwide Barrett registry in the Netherlands.

View Article and Find Full Text PDF
Article Synopsis
  • This study looks at heterologous (mixing vaccine types) versus homologous (same type) COVID-19 vaccination regimens, evaluating their side effects (reactogenicity) and effectiveness (immunogenicity).* -
  • Heterologous vaccines showed lower side effects and better neutralizing response against variants like Delta compared to homologous mRNA vaccines, but both types showed waning immunity over time.* -
  • After a third mRNA dose, most participants had strong neutralizing activity against Delta, but some participants still struggled with the Omicron variant, indicating that updated vaccines specifically for variants would be beneficial.*
View Article and Find Full Text PDF

Background & Aims: Although random histological sampling from the esophagogastric junction (EGJ) after complete eradication of Barrett's esophagus (BE) is recommended, its clinical relevance is questionable. This study aimed to assess the incidence and long-term outcomes of findings from random EGJ biopsies in a nationwide cohort with long-term follow-up.

Methods: We included all patients with successful endoscopic eradication therapy (EET), defined as complete endoscopic eradication of all visible BE (CE-BE), for early BE neoplasia from the Dutch registry.

View Article and Find Full Text PDF

Abnormal-glucose tolerance (Abnl-GT) is due to an imbalance between β-cell function and insulin resistance (IR) and is a major risk factor in cardiovascular disease (CVD). In sub-Saharan Africa, β-cell failure is emerging as an important cause of Abnl-GT (Abnl-GT-β-cell-failure). Visceral adipose tissue (VAT) volume and hyperlipidemia are major contributors to CVD risk when Abnl-GT is due to IR (Abnl-GT-IR).

View Article and Find Full Text PDF

Background: Emerging data suggests that in sub-Saharan Africa β-cell-failure in the absence of obesity is a frequent cause of type 2 diabetes (diabetes). Traditional diabetes risk scores assume that obesity-linked insulin resistance is the primary cause of diabetes. Hence, it is unknown whether diabetes risk scores detect undiagnosed diabetes when the cause is β-cell-failure.

View Article and Find Full Text PDF